Key Insights

Highlights

Treatment Research

2 treatments under study, led by Atorvastatin

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Not Yet Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07883356Phase 2Not Yet Recruiting

Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)

NCT03938545Phase 2TerminatedPrimary

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Showing all 2 trials

Research Network

Common Treatments

  • Atorvastatin1
  • Rvt1401 Administered Via Subcutaneous Injection1

Active Sponsors

  • Immunovant Sciences GmbH1
  • Region Skane1

Top Investigators

Related Conditions

  • Graves Ophthalmopathy1
  • Graves Disease Basedows Disease1
  • Thyroid Eye Disease Ted1
  • Thyroid Eye Disease1
  • Thyroidassociated Ophthalmopathy1

Activity Timeline